ReviewJournal of human immunity2026
ICF syndrome: An epigenetic paradigm for primary immunodeficiencies.
Review in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is a rare autosomal recessive disorder and a paradigmatic epigenetic inborn error of immunity. It is caused by mutations in genes essential for DNA methylation and chromatin regulation - DNMT3B (ICF1), ZBTB24 (ICF2), CDCA7 (ICF3), and HELLS (ICF4). All subtypes share hypogammaglobulinemia, centromeric instability of chromosomes 1, 9, and 16, and characteristic facial anomalies. ICF highlights the role of DNA methylation in genome stability and immune development: DNMT3B deficiency impairs de novo methylation, while the ZBTB24-CDCA7-HELLS axis affects heterochromatin remodeling and methylation maintenance. These defects drive chromosomal abnormalities and immune dysfunction, including impaired B cell maturation and class-switch recombination. Although each subtype shows distinct genotype-phenotype correlations, all converge on altered methylation of repetitive DNA and deregulated immune-related genes. ICF serves as a key model to understand how epigenetic disruption causes immunodeficiency. Limited treatments include supportive care and hematopoietic stem cell transplantation. Insights from ICF also inform other primary immunodeficiencies with epigenetic alterations, such as common variable immunodeficiency.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.